GOSS Stock Forecast & Price Target

Gossamer Bio is in a strong financial position with $57.0M in cash, cash equivalents, and marketable securities as of June 30, 2026, and a cash runway extending through potential approval in August 2027. The recent Virtual NDR with buy-side investors provided granular timing on the regulatory path and reinforced management's totality-of-evidence NDA filing strategy for Seralutinib, further supporting the potential for a launch in 2H27. Additionally, the CT FRI substudy adds biological coherence and a differentiated narrative to the PROSERA readout, though it is not expected to de-risk the potential approval of Seralutinib in PAH and PH-ILD.

Gossamer Bio is facing a number of challenges, including a limited commercial opportunity, concerns around drug-drug interactions with potential combination or sequential use of sotatercept, and a potential data package that may not meet the FDA's criteria for acceptance. In addition, the company's financial position is also a concern, as it plans to reduce its convertible debt through an exchange offer that could result in dilution for current shareholders. The upcoming FDA meeting and potential NDA submission in September 2026 are key catalysts, but the overall outlook for the stock remains high risk and event-driven, leading to a negative outlook from a financial analysis perspective.